Tag: licensing
-
Teva Licenses Pain Relief Antibody for $1.25 Billion
Teva Pharmaceutical Industries is licensing from biotechnology company Regeneron Pharmaceuticals an engineered antibody that targets proteins supporting pain signals.
-
Synthetic Viruses in Gene Therapy Licensed for Production
Techniques from academic research for developing synthetic viruses to deliver gene therapies are being licensed for commercial production and distribution.
-
Nanoparticle Therapy Start-Up Gains $4M in Early Funds
A start-up enterprise developing treatments for autoimmune disorders using protein-laden nanoparticles is raising $4 million in its first venture funding round.
-
Patent Set for Heart Tissue Regeneration Drug
A drug developed by MDI Biological Laboratory that stimulates growth of heart tissue to fix damage from heart attacks is scheduled to receive a U.S. patent.
-
University Spin-Off Developing Sepsis Drug
A spin-off enterprise from University of British Columbia is licensing a cholesterol-lowering drug from drug maker Novartis to develop a treatment for sepsis and other severe infections.
-
Stem Cells, Engineered Protein Reverse Stroke Damage
A combination of stem cells and synthetic human protein was shown in lab mice to repair damaged brain cells a week after an induced stroke.
-
New System Measures Oxygen Levels in ICU Patients
Researchers at University of Oxford in the U.K. designed a device that measures oxygen consumption in critically ill patients, to prevent occurrence of shock.
-
University Spin-Off Developing Chemical ID Devices
A start-up company is licensing research from labs at Harvard University to make portable devices that quickly identify the chemistry of liquids.
-
Amgen, Advaxis Partner on Personal Cancer Immunotherapy
Biological drug maker Amgen is licensing precision immunotherapy technology from Advaxis Inc. to develop treatments for cancer.
-
Univ. Spin-Off Develops New Cybersecurity Paradigm
A start-up enterprise from a university is developing a simplified cybersecurity infrastructure for businesses, and raised $2 million in its first funding round